Lepu Biopharma Co Ltd
Lepu Biopharma Co Ltd is a biotechnology and medical research company that develops and commercializes pharmaceutical products, primarily in the healthcare sector.
Business. Lepu Biopharma Co Ltd (2157.HK) is a biotechnology and medical research company listed on the Hong Kong Stock Exchange. The firm operates within the healthcare sector, focusing on pharmaceuticals and medical research activities. Specific details regarding its operating segments and geographic presence are not provided in the available data. The company is headquartered in China, consistent with its primary listing on the HKEX.
Analyst recommendations
1 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Lepu Biopharma Co Ltd (2157.HK) is a biotechnology and medical research company listed on the Hong Kong Stock Exchange. The firm operates within the healthcare sector, focusing on pharmaceuticals and medical research activities. Specific details regarding its operating segments and geographic presence are not provided in the available data. The company is headquartered in China, consistent with its primary listing on the HKEX.
Lepu Biopharma has a basic and diluted share count of 1.804 billion shares outstanding, indicating no immediate dilution pressure from share-based compensation or convertible instruments. However, liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in source documents.
Profitability and return metrics are not available for Lepu Biopharma, as the valuation snapshot does not include key financial ratios such as ROIC, EBITDA margins, or net profit margins. This lack of data makes it difficult to compare the company's performance against industry benchmarks or cohort medians.
The company's revenue concentration and geographic exposure are not disclosed in the available data. Without segment or geographic breakdowns, it is unclear whether Lepu Biopharma is exposed to specific regional or product-line risks that could affect its financial stability.
Growth trajectory is also unclear, as the outlook for the current and next fiscal years does not include numeric deltas or revenue projections. Analysts have provided a mean price target of 10.38 CNY, with a median and high target also at 10.38 CNY, suggesting a consensus view but no strong buy sentiment.
Risk factors include the inability to assess liquidity risk, which could signal potential financial instability. The company has a low dilution risk, but the absence of detailed risk disclosures in source documents limits the ability to fully evaluate its exposure to market, regulatory, or operational risks.
Recent events and filings do not provide additional insight into the company's strategic direction or operational performance. The lack of recent transcripts or filings suggests limited transparency or public engagement from the company's management.
- Lepu Biopharma has no immediate dilution risk, with basic and diluted shares outstanding being equal.
- Analysts have assigned a neutral to cautious outlook, with a mean recommendation of 2.00 and no strong buy ratings.
- Liquidity risk could not be assessed due to missing balance-sheet data and no going-concern language in source documents.
- The company's profitability, return metrics, and growth trajectory are not available, limiting the ability to benchmark against industry peers.
- Revenue concentration and geographic exposure are not disclosed, making it difficult to assess regional or product-line risks.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Revenue ¥934.9M, +154,2% YoY; Operating income +173,0% YoY.
- ▍Revenue ¥934.9M, +154,2% YoY
- ▍Operating income +173,0% YoY
- ▍Net income +163,5% YoY
- ▍Free cash flow +160,5% YoY
- ▍Net margin 28.0%
Revenue ¥225.4M, +1 347,2% YoY; Operating income +100,7% YoY.
- ▍Revenue ¥225.4M, +1 347,2% YoY
- ▍Operating income +100,7% YoY
- ▍Net income +96,8% YoY
- ▍Free cash flow +104,3% YoY
- ▍Net margin -9.8%
Valuation FY
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Lepu Biopharma Co Ltd Market data — financials · 2026-05-26
- Lepu Biopharma Co Ltd Market data — analyst estimates · 2026-05-26
Ownership & reference
Leadership
- Ziye SuiChief Executive Officer, Executive Director